|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1667 K STREET NW, #1270 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 2558-12
|
||||||||
|
6. House ID# 310910000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Leo C. Jardot, Vice President, Government Relations |
Date | 01/21/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Monitor U.S. trade policies relating to intellectual property protection under the WTO/TRIPS agreement
H.R. 1908 Patent Reform Act of 2007
S. 1145 Patent Reform Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), U.S. Trade Representative (USTR), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Rabinowitz |
|
|
|
Leo |
Jardot |
|
|
|
Bronwen |
Kaye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Vaccine Injury Compensation Program
Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the
Pan American Health Organization; HR 3610 HR 5629
Childhood immunizations
Dietary supplement issues
Implementation issues concerning P.L. 108-173 - The Medicare Prescription Drug, Improvement and Modernization Act of 2003
Drug compounding
Alzheimer's care
Comparative effectiveness - S.3408 - Comparative Effectiveness Research Act of 2008
S. 1695 Biologics Price Competition and Innovation Act of 2007
H.R. 1812 - Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act
Pediatric Studies and Trials
Drug Safety/Clinical Trials
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
S. 623/HR 1038 - Access to Life Saving Medicine Act, Follow-on Biologics
S. 1505 - Affordable Biologics for Consumers Act
H.R. 3610 - Food and Drug Import Safety Act of 2007
S.2029 - Vaccine Safety and Payment
Health care issues
Drug approvals
Reimbursement rates
S. 334 The Healthy Americans Act
H.Con.Res. 342 (BHRT)
FDA Pre-emption
S.3613, H.R. 7114 - Independence at Home Act
S.3409-Drug and Device Accountability Act of 2008
Follow-on biologics
Drug importation and counterfeiting
Drug advertising
Comparative effectiveness
Physician payment disclosure
Hormone replacement therapies
Chronic Illness
International public health issues
International vaccine issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Justice - Dept of (DOJ), Executive Office of the President (EOP), U.S. Trade Representative (USTR), State - Dept of (DOS), Natl Security Agency (NSA), Treasury - Dept of, Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bronwen |
Kaye |
|
|
|
Leo |
Jardot |
|
|
|
Julie |
Rabinowitz |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement
Importation of FDA-approved pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), U.S. Trade Representative (USTR), State - Dept of (DOS), Office of the Vice President of the United States
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Rabinowitz |
|
|
|
Leo |
Jardot |
|
|
|
Bronwen |
Kaye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Taxation of International Operations of U.S. corporations generally; Homeland investment legislation; R&D tax credit;
H.R. 1424 and H.R. 7060;
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Rabinowitz |
|
|
|
Leo |
Jardot |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Vaccines
Medicare chronic disease coverage
Implementation Issues concerning P.L. 108-173 - the Medicare Prescription Drug, Improvement and Modernization Act of 2003
Medicare coverage of pharmaceuticals, Medicare Part D
Issues relating to Medicaid reimbursement for drugs/biologics in Title VI of S.1932-the Deficit Reduction Act of 2005
Pediatric Exclusivity
H.R. 4 - Medicare Prescription Drug Price Negotiation Act
H.R. 3162 - Children's Health and Medicare Protection Act of 2007
S.1893/H.R. 976 - Children's Health Insurance Progam Reauthorization Act of 2007
S. 2499 - Medicare, Medicaid and SCHIP Extension Act of 2007
Chronic care out of pocket costs
S. 2029 - Physician Payments Sunshine Act of 2007
HR 5605 - Physician Payments Sunshine Act of 2007
HR 2185 - Enhanced Healthcare Value for All Act
Medicare Prescription Drug Benefit
Medicaid drug rebate
Medicare Physician Reimbursement package
Medicare and Medicaid Drug Reimbursement
Medicaid Rebate
Medicaid Part D Non-Interference
H.R. 6331/S.3101 - Medicare Improvements for Patients and Providers Act of 2008
S.3118 - Preserving Access to Medicare Act of 2008
S.3613, H.R. 7114 - Independence at Home Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bronwen |
Kaye |
|
|
|
Leo |
Jardot |
|
|
|
Julie |
Rabinowitz |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
FDA reform proposals; Pseudoephedrine
H.R. 970 DXM Distribution Act
S. 1378 DXM Distribution Act
S. 2274 Dextromethorphan Abuse Reduction Act
Monograph System Reform Proposal
S. 2274 DXM Abuse Reduction Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Jardot |
|
|
|
Angela |
Riemer |
|
|
|
Julie |
Rabinowitz |
|
|
|
Bronwen |
Kaye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
S. 623/HR 1038 - Access to Life-Saving Medicine Act, Follow-on Biologics
S.1695 - Biologics Price Competition and Innovation Act of 2007
S.1505- Affordable Biologics for Consumers Act
H.R. 5629 - "Pathway for Biosimilars Act"
H.R. 3610 - Food and Drug Import Safety Act of 2007
S.3409 - Drug and Device Accountability Act of 2008
Biosimilars
Drug Safety
Prescription Drug Importation
Import Safety
Compoundin
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Jardot |
|
|
|
Bronwen |
Kaye |
|
|
|
Julie |
Rabinowitz |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |